Open AccessIncidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries
Author(s) -
Zdravko P. Vassilev,
Montse Soriano Gabarró,
James A. Kaye,
Catherine W. Saltus,
Oliver Riedel,
Oliver Scholle,
Juha Mehtälä,
Pasi Korhonen,
Edeltraut Garbe,
Jihong Zong
Publication year - 2020
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-0315
Subject(s) - medicine , prostate cancer , incidence (geometry) , epidemiology , cancer registry , observational study , german , cancer , oncology , gynecology , physics , archaeology , optics , history
Aim: This reports some of the first incidence rate (IR) estimates of second primary malignancies (SPMs) in men with metastatic castration-resistant prostate cancer (mCRPC) in three countries. Patients & methods: Claims data from the German Pharmacoepidemiological Research Database; registry data from the Prostate Cancer Data Base Sweden; and combined registry-claims data from the US Surveillance, Epidemiology and End Results-Medicare database were analyzed to obtain overall survival and incidence of SPMs in men with mCRPC. Results: SPMs occurred in 308 German (n = 2360), 273 Swedish (n = 2849) and 172 US (n = 2234) men with mCRPC. IRs of SPMs were 79.0 (95% CI: 70.4–88.4), 101.7 (95% CI: 90.3–114.5) and 59 (95% CI: 50–68) per 1000 person-years in German, Swedish and US cohorts, respectively. Conclusion: These studies report some of the first IR estimates of SPMs in men with mCRPC, providing a historical risk estimate of SPM in this patient population.